Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

[1]  L. Aarden,et al.  Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation , 2013, Annals of the rheumatic diseases.

[2]  A. Cheifetz,et al.  Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis , 2013, The American Journal of Gastroenterology.

[3]  T. Matsui,et al.  Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan , 2012, Journal of Gastroenterology.

[4]  T. Matsui,et al.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.

[5]  M. Cottone,et al.  Adalimumab in steroid‐dependent Crohn's disease patients: Prognostic factors for clinical benefit , 2012, Inflammatory bowel diseases.

[6]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[7]  A. Andoh,et al.  Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease , 2012, Journal of Gastroenterology.

[8]  G. Veres,et al.  Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[9]  A. Ford,et al.  Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. , 2011, Journal of Crohn's & colitis.

[10]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[11]  S. Hanauer,et al.  Assessing Response and Loss of Response to Biological Therapies in IBD , 2011, The American Journal of Gastroenterology.

[12]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[13]  W. Reinisch,et al.  Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience , 2011, Alimentary pharmacology & therapeutics.

[14]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[15]  S. Plevy,et al.  Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics , 2011, Inflammatory bowel diseases.

[16]  D. Rubin,et al.  Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents , 2010, Inflammatory bowel diseases.

[17]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[18]  P. Rutgeerts,et al.  The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.

[19]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[20]  B. Dijkmans,et al.  Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. , 2009, Arthritis and rheumatism.

[21]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[22]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[23]  E. Kuipers,et al.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[24]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[25]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[26]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[27]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[28]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[30]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[31]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[32]  L. Mayer,et al.  Evolving paradigms in the pathogenesis of IBD , 2009, Journal of Gastroenterology.

[33]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[34]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.